NOVELTY - Identifying a subject as having a propensity to have an adverse cardiovascular event comprises analyzing a subject sample for an alteration in the nucleic acid sequence of at least one gene consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene relative to a wild-type reference sequence.    USE - The method is useful for identifying a subject as having a propensity to have an adverse cardiovascular event, for identifying a subject as having an allele variant correlated with increased or decreased efficacy of a treatment, for identifying a cardiovascular therapy for a subject, for identifying a subject in need of early and aggressive cardiovascular therapy, or for determining a subject's propensity for an adverse cardiovascular event (claimed).    DETAILED DESCRIPTION - Identifying a subject as having a propensity to have an adverse cardiovascular event comprises analyzing a subject sample for an alteration in the nucleic acid sequence of at least one gene consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene relative to a wild-type reference sequence, the presence or absence of the alteration indicating propensity to have an adverse cardiovascular event. INDEPENDENT CLAIMS are:    (1) a method for identifying a subject as having an allele variant correlated with increased or decreased efficacy of a treatment;    (2) a method for identifying a cardiovascular therapy for a subject;    (3) a method for identifying a subject in need of early and aggressive cardiovascular therapy;    (4) a method for determining a subject's propensity for an adverse cardiovascular event;    (5) a method for identifying a subject in need of prophylactic cardiovascular therapy;    (6) a nucleic acid microarray;    (7) a primer set comprising primers that bind to two or more genes;    (8) a kit for determining the presence or absence of an allelic variant in a biological sample from a subject;    (9) a method for selecting a cardiovascular therapy for a subject;    (10) a representation of the test results of any one of the methods above; and    (11) a pharmaceutical composition.